Walleye Capital’s Pacira BioSciences PCRX Stock Holding History

Walleye Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,400	Closed	-$129K	–	5898
2024 Q1	$129K	Sell	4,400 -7,200	-62%	-$221K	﹤0.01%	4246
2023 Q4	$391K	Buy	+11,600	New	+$339K	﹤0.01%	3134
2023 Q1	–	Sell	-1,000	Closed	-$38.6K	–	4264
2022 Q4	$38.6K	Hold	1,000	–	–	﹤0.01%	2578
2022 Q3	$53K	Buy	+1,000	New	+$55.6K	﹤0.01%	2574
2020 Q2	–	Sell	-5,800	Closed	-$194K	–	880
2020 Q1	$194K	Sell	5,800 -5,900	-50%	-$245K	0.04%	449
2019 Q4	$530K	Buy	+11,700	New	+$497K	0.03%	643
2019 Q3	–	Sell	-7,500	Closed	-$326K	–	2171
2019 Q2	$326K	Buy	+7,500	New	+$318K	0.04%	695
2018 Q3	$1.16M	Buy	+23,500	New	+$1.02M	0.54%	53

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Walleye Capital's PCRX Position: Q2 2025 in Review

Walleye Capital sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 119,857 shares — an estimated $2.98M sold.

Walleye Capital first reported a position in PCRX in Q2 2019 and held it in 16 quarters. The position peaked at $10.3M in Q1 2022. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

Walleye Capital reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
Walleye Capital sold 119,857 Pacira BioSciences shares in Q2 2025, an estimated $2.98M.
Walleye Capital first reported a position in Pacira BioSciences in Q2 2019 and held it in 16 quarters.
Walleye Capital's Pacira BioSciences position peaked at $10.3M in Q1 2022.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.